Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as KYTH-105, AGN-241679
Setipiprant · 1 trial · 1 indication
TAHC was measured using digital imaging analysis and was reported in terminal hairs/centimeters square (cm\^2). TAHC is a standardized objective quantification of the number of hairs within a prespecified target area of the scalp at different timepoints, using macrophotography digital images. The total number of terminal hairs (hair width ≥ 30 μm) was calculated from macrophotographs. The target area used to count TAHC was a 1 cm\^2 circular area of clipped hair (length approximately 1 mm) located at the anterior leading edge of the vertex thinning area of the scalp and centered with a semi-permanent microdot tattoo to ensure the same target area was reproduced at each visit. A positive change from Baseline indicated improvement (increase in the number of terminal hairs). Missing data are imputed up to Week 24 using last observation carried forward (LOCF) method.
The SSA consisted of a single-item measure that assesses each participant's perception of change in scalp hair growth. The participant used a standardized global photograph of his scalp taken at the Screening visit presented side by side with a standardized global photograph taken at the postbaseline visit to give a comparative score. The photographs were presented in a blinded and randomized manner to avoid influencing the participant, and response options were on a 7-point ordinal scale (where, -3=Greatly decreased, -2=Moderately decreased, -1=Slightly decreased, 0=No change, +1=Slightly increased, +2=Moderately increased and +3=Greatly increased). The higher the mean SSA value, the more the perception of hair growth from baseline. Missing data are imputed up to Week 24 using LOCF method.
| Arm | Type | Description |
|---|---|---|
| Setipiprant | EXPERIMENTAL | Setipiprant 1000 mg (2 X 500 mg) tablets, orally, BID at 12-hour intervals for 24 weeks. |
| Placebo | PLACEBO_COMPARATOR | Two placebo tablets BID at 12-hour intervals for 24 weeks. |
| Finasteride | ACTIVE_COMPARATOR | Finasteride 1 mg tablet, orally, once daily for 24 weeks. |
| Name | Type | Description |
|---|---|---|
| Setipiprant | DRUG | Setipiprant tablets, orally, BID for 24 weeks. |
| Placebo | DRUG | Placebo tablets, orally, BID for 24 weeks. |
| Finasteride | DRUG | Finasteride tablet, orally, once daily for 24 weeks. |
Inclusion Criteria: * Participant has androgenetic alopecia (AGA) * Participant agrees to maintain current hair care regimen, refraining from hair weaving, hair colorants or dyes and non-study hair growth products during the study. Exclusion Criteria: * History of hair loss for reasons other than...
Top 9 of 12 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Pfizer Inc. | PFE | 8 | PHASE3 | Ritlecitinib |
| AbbVie, Inc. | ABBV | 4 | PHASE3 | Upadacitinib |
| Veradermics, Incorporated | MANE | 4 | PHASE3 | VDPHL01 |
| Eli Lilly and Company | LLY | 2 | PHASE3 | Baricitinib, LY4005130 |
| Q32 Bio Inc | QTTB | 1 | PHASE2 | Bempikibart |
| Forte Biosciences Inc. | FBRX | 1 | PHASE1 | FB102 |
| Absci Corporation | ABSI | 1 | PHASE1 | ABS-201 |
| HCW Biologics, Inc. | HCWB | 1 | PHASE1 | HCW9302 |
| Regeneron Pharmaceuticals, Inc. | REGN | 1 | PHASE2 | dupilumab |
Setipiprant is being studied for the treatment of androgenetic alopecia, a form of hair loss. It is an investigational oral small molecule developed by AbbVie Inc. and has been evaluated in a Phase 2 clinical trial in males with this condition. It is not approved for any indication.
Setipiprant targets PTGDR2, also known as the DP2 receptor, where it acts as an antagonist. By blocking this receptor, the drug is designed to interfere with a pathway thought to contribute to hair follicle miniaturization in androgenetic alopecia.
Setipiprant is being developed by AbbVie Inc., which trades on the New York Stock Exchange under the ticker ABBV. The company sponsored the Phase 2 clinical trial of the drug in androgenetic alopecia.
Setipiprant is in Phase 2 development. It has completed one Phase 2 clinical trial in androgenetic alopecia and is not currently approved by the FDA for any indication. No active trials are ongoing.
Setipiprant has been evaluated in one completed Phase 2 trial, NCT02781311, titled A Safety and Efficacy Study of Setipiprant Tablets in Androgenetic Alopecia in Males. The trial enrolled 169 male participants aged 18 years and older in the United States and was randomized, double-blind, and placebo-controlled.